Literature DB >> 27272452

Risk of serious bloodstream infections is low in pediatric hematopoietic stem cell transplant (HSCT) recipients with fevers due to antithymocyte globulins and alemtuzumab.

B Horn1, S O'Kane1, R L Wattier2, J T Wahlstrom1, A Melton1, M J Cowan1, C C Dvorak1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27272452      PMCID： PMC9241576          DOI： 10.1038/bmt.2016.157

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.174


× No keyword cloud information.
  10 in total

1.  Repeat blood cultures in children with persistent fever and neutropenia: Diagnostic and clinical implications.

Authors:  Rachel L Wattier; Christopher C Dvorak; Andrew D Auerbach; Peggy S Weintrub
Journal:  Pediatr Blood Cancer       Date:  2015-03-01       Impact factor: 3.167

2.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

3.  The incidence and significance of fevers during treatment with antithymocyte globulin for aplastic anaemia.

Authors:  C Dearden; T Foukaneli; P Lee; E C Gordon-Smith; J C Marsh
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

4.  Two-sided confidence intervals for the single proportion: comparison of seven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

5.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

6.  Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.

Authors:  Jason Law; Morton J Cowan; Christopher C Dvorak; Lisa Musick; Janel R Long-Boyle; Lee Ann Baxter-Lowe; Biljana Horn
Journal:  Biol Blood Marrow Transplant       Date:  2012-05-15       Impact factor: 5.742

7.  Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: a prospective multicenter evaluation.

Authors:  Milena Villarroel; Carmen L Avilés; Pamela Silva; Ana M Guzmán; Helena Poggi; Ana M Alvarez; Ana Becker; Miguel O'ryan; Carmen Salgado; Santiago Topelberg; Juan Tordecilla; Mónica Varas; Tamara Viviani; Marcela Zubieta; María E Santolaya
Journal:  Pediatr Infect Dis J       Date:  2010-09       Impact factor: 2.129

8.  Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab.

Authors:  Laura Willemsen; Cornelia M Jol-van der Zijde; Rick Admiraal; Hein Putter; Anja M Jansen-Hoogendijk; Monique M Ostaijen-Ten Dam; Juul T Wijnen; Charlotte van Kesteren; Jacqueline L M Waaijer; Arjan C Lankester; Robbert G M Bredius; Maarten J D van Tol
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-05       Impact factor: 5.742

9.  A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation.

Authors:  Elio Castagnola; Vincenzo Fontana; Ilaria Caviglia; Silvia Caruso; Maura Faraci; Francesca Fioredda; Maria Luisa Garrè; Cristina Moroni; Massimo Conte; Giuseppe Losurdo; Franca Scuderi; Roberto Bandettini; Paolo Tomà; Claudio Viscoli; Riccardo Haupt
Journal:  Clin Infect Dis       Date:  2007-10-05       Impact factor: 9.079

10.  Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation.

Authors:  Thomas Lehrnbecher; Robert Phillips; Sarah Alexander; Frank Alvaro; Fabianne Carlesse; Brian Fisher; Hana Hakim; Maria Santolaya; Elio Castagnola; Bonnie L Davis; L Lee Dupuis; Faith Gibson; Andreas H Groll; Aditya Gaur; Ajay Gupta; Rejin Kebudi; Sérgio Petrilli; William J Steinbach; Milena Villarroel; Theoklis Zaoutis; Lillian Sung
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.